T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev

AIDS

Volumn 16, Issue 16, 2002, Pages 2137-2143

  MacGregor, Rob Roy ^a   Ginsberg, Richard ^c   Ugen, Kenneth E ^b   Baine, Yaela ^d   Kang, Christina U ^a   Tu, Xin M ^a   Higgins, Terry ^c   Weiner, David B ^a,e   Boyer, Jean D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c PFIZER INC   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cellular immune response; Clinical studies; DNA vaccines

Indexed keywords

BUPIVACAINE; DNA VACCINE; GAMMA INTERFERON; REV PROTEIN; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CAPILLARY RESISTANCE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; ERYTHEMA; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NORMAL HUMAN; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AIDS VACCINES; ANTIBODY FORMATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, ENV; GENE PRODUCTS, REV; HIV-1; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MIDDLE AGED; T-LYMPHOCYTES; VACCINES, DNA;

EID: 0037045012     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211080-00005     Document Type: Article

References (40)

1. UNAIDS. AIDS Epidemic Update: December 1999. Geneva, Switzerland: UNAIDS Joint United Nations Programme on HIV/ AIDS.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
3. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
4. Fauci AS. The AIDS epidemic. Considerations for the 21st century. N Engl J Med 1999, 341:1046-1050.
5. McDonnell WM, Askari FK. DNA vaccines. N Engl J Med 1996, 335:42-45.
6. Ulmer JB, Donnelly J, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1748.
7. Xiang ZQ, Spitalnik S, Tran M, et al. Vaccination with a plasmid vector carrying the rabies glycoprotein gene induces protective immunity against rabies virus. Virology 1994, 199:132-140.
8. Babiuk LA, Lewis PJ, Cox G, et al. DNA immunization with bovine herpesvirus-1 genes. In: DNA Vaccine: A New Era in Vaccinology, Vol. 772. Edited by Liu M, Hilleman MR, Kurth R. New York: New York Academy of Sciences; 1995:47-63.
9. Whalen RG, Leclerc C, Deriaud E, et al. DNA-mediated immunization to the hepatitis B surface antigen: Activation and entrainment of the immune response. In: DNA Vaccine: A New Era in Vaccinology, Vol. 772. Edited by Liu M, Hilleman MR, Kurth R. New York: New York Academy of Sciences; 1995:64-76.
10. Brinster C, Muguet S, Lone YC, et al. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 2001, 34:1206-1217.
11. Bourne N, Stanberry LR, Bernstein DI, et al. DNA immunization against experimental herpes simples virus infection. J Infect Dis 1996, 173:800-807.
12. Wang B, Ugen KE, Srikantin V, et al. Gene inoculation generates immune responses against HIV type 1. Proc Natl Acad Sci USA 1993, 90:4156-4160.
13. Amara, RR., Villinger, F., Altman, JD. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2000, 292:93-95.
14. Barouch DH. Craiu A. Kuroda MJ. et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000, 97:4192-4197.
15. Muthumani K, Bagarazzi ML, Conway D, et al. Inclusion of VPR accessory gene plasmid in a plasmid vaccine cocktail markedly reduces vaccine effectiveness and antigen specific effector T cell function in vivo resulting in CD4 cell loss and increased viral loads in Rhesus macaques. J Primatol, in press.
16. MacGregor RR, Boyer J, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J Infect Dis 1998, 178:92-100.
17. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351:1320-1325.
18. MacGregor RR, Boyer J, Ginsberg R, et al. Administration of a facilitated DNA plasmid vaccine containing HIV-1 env/rev and gag/pol genes to HIV-infected patients also receiving highly active therapy. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January-February 1999 [abstract 347].
19. Boyer JD, Cohen AD, Vogt S, et al. Vaccination of seronegative volunteers with an HIV-1 env/rev DNA vaccine induces antigen specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 2000, 181:476-483.
20. Ugen KE, Srikantan V, Goedert JJ, Nelson RP, Williams WV, Weiner, DB. Vertical transmission of human immunodeficiency virus type 1: Seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein. J Infect Dis 1997, 175: 63-69.
21. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: A randomized, placebo-controlled trial. Arch Intern Med 1996, 156:1546-1550.
22. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993, 270:1826-1831.
23. Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993, 91:759-765.
24. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: New insights. Immunol Today 1994, 15:575-581.
25. Chehimi J, Starr SE, Frank I, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994, 179:1361-1366.
26. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994, 93:768-775.
27. Erard F, Dunbar PR, Le Gros G. The IL4- induced switch of CD8+ T cells to a TH2 phenotype and its possible relationship to the onset of AIDS. Res Immunol 1994, 145:643-645.
28. Meyaard L, Otto SA, Keet IP, van Lier RA, Miedema F. Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. Blood 1994, 84:4262-4268.
29. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 1994, 265:244-248.
30. Graziosi C, Pantaleo G, Gantt KR, et al. Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 1994, 265:248-252.
31. Fakoya A, Matear PM, Filley E, et al. HIV infection alters the production of both type 1 and 2 cytokines but does not induce a polarized type 1 or 2 state. AIDS 1997, 11:1445-1452.
32. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994, 94:2435-2442.
33. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993, 262:1721-1724.
34. Blauvelt A, Chougnet C, Shearer GM, Katz SI. Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12. J Clin Invest 1996, 97:1550-1555.
35. Estaquier J, Idziorek T, Zou W, et al. T helper type 1/T helper type 2 cytokines and T cell death: Preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995, 182:1759-1767.
36. Rosenberg, ES, Altfeld, M, Poon, SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523.
37. Robinson HL, Montefiori DC, Johnson RP. et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nature Med 1999, 5:526-534.
38. Barouch, DH, Santra, S, Schmitz, JE, et al. Control of viremia and prevention of clinical AIDS in Rhesus monkeys by cytokine augmented DNA vaccination. Science 2000, 290:486-492.
39. Shedlock D, Weiner DB. Cellular and molecular mechanisms of host defense and inflammation. J Leukocyte Biol 2000, 68:793-806.
40. Kim, J, Ayyavoo, V, Bagarazzi, ML, et al. In vivo engineering of a cellular immune response by co-administration of IL-12 expression vector with a DNA immunogen. J Immun 1997, 158:816.